On May 27, 2022 CEL-SCI Corporation (NYSE American: CVM) reported the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) has published two abstracts related to CEL-SCI’s pivotal Phase 3 Multikine (Leukocyte Interleukin, Inj.)* head and neck cancer clinical trial (Press release, Cel-Sci, MAY 27, 2022, View Source [SID1234615202]). The poster will be presented by CEL-SCI’s Chief Scientific Officer, Eyal Talor, Ph.D., at the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting to be held June 3-7, 2022 in Chicago, Illinois.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract titles and corresponding links are as follows:

"Leukocyte interleukin injection (LI) immunotherapy extends overall survival (OS) in treatment-naive low-risk (LR) locally advanced primary squamous cell carcinoma of the head and neck: The IT-MATTERS study." Link to abstract: View Source
"Novel algorithm for assigning risk/disease-directed treatment (DDT) choice in locally advanced primary squamous cell carcinoma of the head and neck (SCCHN): Using pretreatment data only." Link to abstract: View Source
ASCO is the largest cancer meeting in the world, bringing together thousands of cancer experts from academia, industry, patient advocacy and policy.